Analyst firms · HSBC · MRNA

HSBC MRNA price target and rating history

Moderna Inc. (MRNA) · Health Care

HSBC rates Moderna Inc. (MRNA) Buy with a $58 price target, as of its latest action on Nov 18, 2024. It has published 5 rating actions on MRNA since July 2023, including 3 upgrades and 1 downgrade. Across 6 firms with a MRNA price target in the last 12 months, the median target is $57.

Current rating

Buy

Price target

$58

Median target, all firms

$57

Actions on MRNA

5

HSBC price target on MRNA

Every HSBC rating on MRNA

• Nov 18, 2024
  UpgradeHSBC upgrades to Buy from Hold, price target $58
• Aug 28, 2024
  UpgradeHSBC upgrades to Hold from Reduce, price target $82
• Feb 26, 2024
  DowngradeHSBC downgrades to Reduce from Hold, price target $75 to $86
• Nov 3, 2023
  UpgradeHSBC upgrades to Hold from Reduce, price target $89 to $69
• Jul 14, 2023
  InitiateHSBC starts coverage at Reduce, price target $97

How other firms rate MRNA

Each firm's latest rating and stated target in the last 12 months.

Questions about HSBC and MRNA

What is HSBC's price target for MRNA?

HSBC's latest stated price target for Moderna Inc. (MRNA) is $58, from its action on Nov 18, 2024.

What is HSBC's rating on MRNA?

HSBC rates MRNA Buy, a bullish rating, as of Nov 18, 2024.

When did HSBC last change its view on MRNA?

On Nov 18, 2024, HSBC upgrades to Buy from Hold, price target $58.

How does HSBC's MRNA target compare with other analysts?

Across 6 firms with a MRNA price target in the last 12 months, the median target is $57.

More MRNA rating histories

• William Blair3
• Argus Research3
• Wolfe Research3
• BofA Securities3
• Barclays4
• UBS3
• Jefferies5
• Oppenheimer3
• Deutsche Bank7
• TD Cowen4
• Leerink Partners5
• Morgan Stanley5
• Piper Sandler3

All HSBC ratingsMRNA news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.